AMPLIA THERAPEUTICS LIMITED

Insiders Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Delayed Australian S.E. Other stock markets 02:34:06 16/05/2024 BST			5-day change	1st Jan Change
0.062 ^AUD	+1.64%		+1.67%	-23.75%

05-15	Amplia Therapeutics Completes AU$4.27 Million Entitlement Offer; Shares Up 9%	MT
04-16	Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amplia Therapeutics Appoints CFO	25/09/23	MT
Amplia Therapeutics Gets Nod to Name Drug AMP945 Narmafotinib	23/06/23	MT
Amplia Therapeutics Appoints Managing Director and CEO	07/11/22	MT
Amplia Therapeutics Limited Appoints Christopher Burns as Managing Director, Effective December 5, 2022	06/11/22	CI
Amplia Therapeutics Limited Appoints Christopher Burns as Chief Executive Officer, Effective December 5, 2022	06/11/22	CI
Amplia Therapeutics' CEO Resigns; Shares Plunge 13%	12/09/22	MT
Amplia Therapeutics Announces Executive Changes	12/09/22	CI
Amplia Therapeutics Limited Announces CEO Changes	12/09/22	CI
Amplia Therapeutics Limited Appoints Jane Bell to Board of Directors	11/04/21	CI
Amplia Therapeutics Limited Appoints Dr. Mark Devlin as Chief Scientific Officer	31/08/20	CI
Amplia Therapeutics Limited Appoints Professor Paul Timpson to Its Scientific Advisory Board	12/02/20	CI
Amplia Therapeutics Limited Appoints Dr. John Lambert as Managing Director	06/02/20	CI
Amplia Therapeutics Limited Announces Management Changes	05/02/20	CI
Amplia Therapeutics Limited Announces Executive Changes	24/06/19	CI
INNATE IMMUNOTHERAPEUTICS LTD will Change its Name to Amplia Therapeutics Limited	13/09/18	CI
Innate Immunotherapeutics Limited Appoints Dr. Warwick Tong as Chairman	28/05/18	CI
Innate Immunotherapeutics Limited Announces Executive Changes	04/05/18	CI
Innate Immunotherapeutics Limited Approves Director Appointments	26/04/18	CI
Innate Immunotherapeutics Limited Appoints Robert Peach as a Non-Executive Director to its Board	02/09/15	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer